department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

Licart · pharmadog

pharmadog
drugs
Licart

drug

patient view →

diclofenac ER

Marketedupdated 2mo ago

by IBSA Pharma Inc

Approved

community read0 votes

Small molecule drug with a maximum clinical stage of Approval (across all indications), with 15 approved and 20 investigational indications.

all catalysts(1)

phase 2 initiation · 1

phase 2 initiation

Goa Medical College — diclofenac (Phase II Trial Initiation)

News(0)

no news has mentioned this drug yet

brand

Licart

generic

diclofenac

MOA

Cyclooxygenase inhibitor

indication

Pain

phase

marketed

Data sources

ClinicalTrials.gov

last refreshed 1h ago

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

Patent cliff

source: FDA Orange Book

first barrier falls

Apr 23, 2030

~3.8 years out

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (16)

Feb 20, 2035method-of-use (U-3393)US 11344520
Feb 20, 2035method-of-use (U-3393)US 11351133
Apr 23, 2030formulationUS 86795443.8y
Apr 23, 2030formulationUS 86795443.8y
Apr 23, 2030method-of-use (U-55)US 89993873.8y
Apr 23, 2030method-of-use (U-55)US 89993873.8y
Apr 23, 2030formulationUS 90177213.8y
Apr 23, 2030formulationUS 90177213.8y
Apr 23, 2030formulationUS 91738543.8y
Apr 23, 2030formulationUS 91738543.8y
Apr 23, 2030method-of-use (U-55)US 91800953.8y
Apr 23, 2030method-of-use (U-55)US 91800953.8y
Apr 23, 2030formulationUS 91800963.8y
Apr 23, 2030formulationUS 91800963.8y
Apr 23, 2030method-of-use (U-55)US 91863283.8y
Apr 23, 2030method-of-use (U-55)US 91863283.8y

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

🐶 often sniffed alongside

top 8

tagApproval54 co-mentions · 20 sources
drugdiclofenac44 co-mentions · 34 sources
drugDICLOFENAC SODIUM19 co-mentions · 16 sources
drugdiclofenac sodium ER19 co-mentions · 16 sources
drugdiclofenac sodium SR19 co-mentions · 16 sources
drugPennsaid19 co-mentions · 16 sources
drugdiclofenac sodium DR19 co-mentions · 16 sources
drugDictor19 co-mentions · 16 sources

Trials studying diclofenac ER

phase2Sustained Acoustic Medicine for Symptomatic Treatment of Knee Pain Related to Osteoarthritiscompletedn=307
phase2Long Duration High Frequency Ultrasound for the Treatment of Osteoarthritisnot yet recruitingn=240
phase3Counterpain PXM Versus Diclofenac Versus Piroxicamcompletedn=180
phase3A Study to Evaluate Efficacy and Safety of AMZ001 for the Treatment of Knee Osteoarthritis Symptomsactive not recruitingn=540
phase1Comparison of Diclofenac Systemic Exposure From Two Different Products (AMZ001 and Diclofenac Diethylammonium 1.16% Gel) in Healthy Participants After Repeated Topical Administrations for 7 Days.completedn=34
N/ATo Check Dermatological Safety of Test Products by 24 Hours Patch Testingcompletedn=26
phase1A Study of Diclofenac Gel in Women With Primary Dysmenorrheacompletedn=42
phase3A 12-week Study to Evaluate the Efficacy and Safety of HP-5000 in Subjects With Osteoarthritis Pain of the Kneecompletedn=370

more trials →